المؤلفون: Fontán-Vela, Mario, Kissling, Esther, Nicolay, Nathalie, Braeye, Toon, Van Evercooren, Izaak, Holm Hansen, Christian, Emborg, Hanne-Dorthe, Fabiani, Massimo, Mateo-Urdiales, Alberto, AlKerwi, Ala'a, Schmitz, Susanne, Castilla, Jesús, Martínez-Baz, Iván, de Gier, Brechje, Hahné, Susan, Meijerink, Hinta, Starrfelt, Jostein, Nunes, Baltazar, Caetano, Constantino, Derrough, Tarik, Nardone, Anthony, Monge Corella, Susana, VEBIS-Lot4 working group

مصطلحات موضوعية: COVID-19, SARS-CoV-2, Cohort design, Electronic health records, Hospitalisation, Multi-country study, Vaccine effectiveness, Humans, Aged, 80 and over, Retrospective Studies, Vaccine Efficacy, Europe, Hospitalization

الوصف: To monitor relative vaccine effectiveness (rVE) against COVID-19-related hospitalisation of the first, second and third COVID-19 booster (vs complete primary vaccination), we performed monthly Cox regression models using retrospective cohorts constructed from electronic health registries in eight European countries, October 2021-July 2023. Within 12 weeks of administration, each booster showed high rVE (≥ 70% for second and third boosters). However, as of July 2023, most of the relative benefit has waned, particularly in persons ≥ 80-years-old, while some protection remained in 65-79-year-olds. ; Sí

العلاقة: https://doi.org/10.2807/1560-7917.ES.2024.29.1.2300670Test; Euro Surveill. 2024 Jan;29(1):2300670.; http://hdl.handle.net/20.500.12105/18983Test; Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

الإتاحة: https://doi.org/20.500.12105/18983Test
https://doi.org/10.2807/1560-7917.ES.2024.29.1.2300670Test
https://hdl.handle.net/20.500.12105/18983Test

المؤلفون: Kislaya, Irina, Sentís, Alexis, Starrfelt, Jostein, Nunes, Baltazar, Martínez-Baz, Iván, Nielsen, Katrine Finderup, AlKerwi, Ala'a, Braeye, Toon, Fontán-Vela, Mario, Bacci, Sabrina, Meijerink, Hinta, Castilla, Jesús, Emborg, Hanne-Dorthe, Hansen, Christian Holm, Schmitz, Susanne, Van Evercooren, Izaak, Valenciano, Marta, Nardone, Anthony, Nicolay, Nathalie, Monge Corella, Susana, VEBIS-Lot4 working group

المساهمون: Unión Europea. European Centre for Disease Prevention and Control (ECDC)

مصطلحات موضوعية: COVID-19, COVID-19-related death, SARS-CoV-2, Cohort design, Hospitalization, Vaccine effectiveness, COVID-19 Vaccines, Humans, Aged, Vaccine Efficacy, Registries, Electronics

الوصف: Background: Within the ECDC-VEBIS project, we prospectively monitored vaccine effectiveness (VE) against COVID-19 hospitalisation and COVID-19-related death using electronic health registries (EHR), between October 2021 and November 2022, in community-dwelling residents aged 65-79 and ≥80 years in six European countries. Methods: EHR linkage was used to construct population cohorts in Belgium, Denmark, Luxembourg, Navarre (Spain), Norway and Portugal. Using a common protocol, for each outcome, VE was estimated monthly over 8-week follow-up periods, allowing 1 month-lag for data consolidation. Cox proportional-hazards models were used to estimate adjusted hazard ratios (aHR) and VE = (1 - aHR) × 100%. Site-specific estimates were pooled using random-effects meta-analysis. Results: For ≥80 years, considering unvaccinated as the reference, VE against COVID-19 hospitalisation decreased from 66.9% (95% CI: 60.1; 72.6) to 36.1% (95% CI: -27.3; 67.9) for the primary vaccination and from 95.6% (95% CI: 88.0; 98.4) to 67.7% (95% CI: 45.9; 80.8) for the first booster. Similar trends were observed for 65-79 years. The second booster VE against hospitalisation ranged between 82.0% (95% CI: 75.9; 87.0) and 83.9% (95% CI: 77.7; 88.4) for the ≥80 years and between 39.3% (95% CI: -3.9; 64.5) and 80.6% (95% CI: 67.2; 88.5) for 65-79 years. The first booster VE against COVID-19-related death declined over time for both age groups, while the second booster VE against death remained above 80% for the ≥80 years. Conclusions: Successive vaccine boosters played a relevant role in maintaining protection against COVID-19 hospitalisation and death, in the context of decreasing VE over time. Multicountry data from EHR facilitate robust near-real-time VE monitoring in the EU/EEA and support public health decision-making. ; European Centre for Disease Prevention and Control, Grant/Award Numbers: ECDC/2021/018, RS/2022/DTS/24104 ; Sí

العلاقة: https://doi.org/10.1111/irv.13195Test; Influenza Other Respir Viruses. 2023 Nov;17(11):e13195.; http://hdl.handle.net/20.500.12105/16894Test; Influenza and other respiratory viruses

الإتاحة: https://doi.org/20.500.12105/16894Test
https://doi.org/10.1111/irv.13195Test
https://hdl.handle.net/20.500.12105/16894Test

المؤلفون: Sentís, Alexis, Kislaya, Irina, Nicolay, Nathalie, Meijerink, Hinta, Starrfelt, Jostein, Martínez-Baz, Iván, Castilla Catalán, Jesús, Nielsen, Katrine Finderup, Hansen, Christian Holm, Emborg, Hanne-Dorthe, Nardone, Anthony, Derrough, Tarik, Valenciano, Marta, Nunes, Baltazar, Monge, Susana, VEBIS-Lot4 working group, Larrauri, Amparo, Mazagatos, Clara

المساهمون: Unión Europea. European Centre for Disease Prevention and Control (ECDC)

مصطلحات موضوعية: COVID-19, Delta variant, Omicron variant, Vaccination booster dose, Vaccination primary course, Vaccine effectiveness, COVID-19 Vaccines, Aged, Electronics, Hospitalization, Humans, Pilot Projects, Registries, Vaccine Efficacy

الوصف: By employing a common protocol and data from electronic health registries in Denmark, Navarre (Spain), Norway and Portugal, we estimated vaccine effectiveness (VE) against hospitalisation due to COVID-19 in individuals aged ≥ 65 years old, without previous documented infection, between October 2021 and March 2022. VE was higher in 65-79-year-olds compared with ≥ 80-year-olds and in those who received a booster compared with those who were primary vaccinated. VE remained high (ca 80%) between ≥ 12 and < 24 weeks after the first booster administration, and after Omicron became dominant. ; All the organisations involved have received funding from the European Centre for Disease Prevention and Control (ECDC) implementing Framework Contract ECDC/2021/018 ‘Vaccine effectiveness and impact of COVID-19 vaccines through routinely collected exposure and outcome using health registries’ (RS/2022/DTS/24104). ; Sí

العلاقة: Euro Surveill. 2022 Jul;27(30):2200551.; http://hdl.handle.net/20.500.12105/15461Test; Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

الإتاحة: https://doi.org/20.500.12105/15461Test
https://doi.org/10.2807/1560-7917.ES.2022.27.30.2200551Test
https://hdl.handle.net/20.500.12105/15461Test

المؤلفون: Kafatos, G, Andrews, N, McConway, K J, Anastassopoulou, C, Barbara, C, De Ory, Fernando, Johansen, K, Mossong, J, Prosenc, K, Vranckx, R, Nardone, A, Pebody, R, Farrington, P

المساهمون: European Commission

مصطلحات موضوعية: ESEN2, Seroprevalence, Serosurvey, Standardization, Vaccination, Adolescent, Adult, Chickenpox, Child, Preschool, Diphtheria, Diphtheria Toxoid, Europe, Hepatitis A, Humans, Infant, Measles, Mumps, Reference Standards, Rubella, Seroepidemiologic Studies, Viral Vaccines, Young Adult

الوصف: The aim of the European Sero-Epidemiology Network 2 (ESEN2) project was to estimate age-specific seroprevalence for a number of vaccine-preventable diseases in Europe. To achieve this serosurveys were collected by 22 national laboratories. To adjust for a variety of laboratory methods and assays, all quantitative results were transformed to a reference laboratory's units and were then classified as positive or negative to obtain age-specific seroprevalence. The aim of this study was to assess the value of standardization by comparing the crude and standardized seroprevalence estimates. Seroprevalence was estimated for measles, mumps, rubella, diphtheria, varicella zoster and hepatitis A virus (HAV) and compared before and after serological results had been standardized. The results showed that if no such adjustment had taken place, seroprevalence would have differed by an average of 3·2% (95% bootstrap interval 2·9-3·6) although this percentage varied substantially by antigen. These differences were as high as 16% for some serosurveys (HAV) which means that standardization could have a considerable impact on seroprevalence estimates and should be considered when comparing serosurveys performed in different laboratories using different assay methods. ; We thank all the ESEN2 members who contributed to the collection and testing of the serological samples included in this paper. The ESEN2 project was funded by the European Commission (contract number QLK2-CT-2000–00542), national governments and other national funding sources. ; Sí

العلاقة: Publisher's version; https://doi.org/10.1017/S095026881400301XTest; info:eu-repo/grantAgreement/EU/QLK2-CT-2000–00542; Epidemiol Infect. 2015 Aug;143(11):2269-78.; http://hdl.handle.net/20.500.12105/11473Test; Epidemiology and infection

الإتاحة: https://doi.org/20.500.12105/11473Test
https://doi.org/10.1017/S095026881400301XTest
https://hdl.handle.net/20.500.12105/11473Test

المؤلفون: Eriksen, J, Davidkin, I, Kafatos, G, Andrews, N, Barbara, C, Cohen, D, Duks, A, Griskevicius, A, Johansen, K, Bartha, K, Kriz, B, Mitis, G, Mossong, J, Nardone, A, O'Flanagan, D, De Ory, Fernando de, Pistol, A, Theeten, H, Prosenc, K, Slacikova, M, Pebody, R

المساهمون: Unión Europea. Comisión Europea

مصطلحات موضوعية: Epidemiology, Mumps, Outbreaks, Serology, Vaccination (immunization), Disease Outbreaks, Mumps Vaccine, Adolescent, Adult, Antibodies, Viral, Child, Preschool, Europe, Female, Humans, Immunization Schedule, Incidence, Infant, Male, Middle Aged, Mumps virus, Seroepidemiologic Studies, Vaccination, Young Adult

الوصف: Mumps outbreaks have recently been recorded in a number of highly vaccinated populations. We related seroprevalence, epidemiological and vaccination data from 18 European countries participating in The European Sero-Epidemiology Network (ESEN) to their risk of mumps outbreaks in order to inform vaccination strategies. Samples from national population serum banks were collected, tested for mumps IgG antibodies and standardized for international comparisons. A comparative analysis between countries was undertaken using age-specific mumps seroprevalence data and information on reported mumps incidence, vaccine strains, vaccination programmes and vaccine coverage 5-12 years after sera collection. Mean geometric mumps antibody titres were lower in mumps outbreak countries [odds ratio (OR) 0·09, 95% confidence interval (CI) 0·01-0·71)]. MMR1 vaccine coverage ⩾95% remained protective in a multivariable model (P < 0·001), as did an interval of 4-8 years between doses (OR 0·08, 95% CI 0·01-0·85). Preventing outbreaks and controlling mumps probably requires several elements, including high-coverage vaccination programmes with MMR vaccine with 4-8 years between doses. ; This work was partially funded by a grant from the European Commission (contract number QLK2-CT-2000-00542). ; Sí

العلاقة: https://doi.org/10.1017/S0950268812001136Test; info:eu-repo/grantAgreement/EC/QLK2-CT-2000-00542; Epidemiol Infect. 2013 Mar;141(3):651-66.; http://hdl.handle.net/20.500.12105/11498Test; Epidemiology and infection

الإتاحة: https://doi.org/20.500.12105/11498Test
https://doi.org/10.1017/S0950268812001136Test
https://hdl.handle.net/20.500.12105/11498Test